| Thursday, March 20th, 2025 |
|
| 13:00 – 19:00 | REG Working Group Meetings |
| Friday , March 21st, 2025 |
|
| 08:50 – 09:00 | Welcome Joan Β. Soriano, REG President |
| 09:00 – 10:00 | Inhaler Session - Propellants, planet, and the patient - the real-life impact Chair: Omar Usmani & Mark Levy What does it mean to the Regulator? Maureen Donahue Hardwick What does it mean to the Industry? John Bell What does it mean to the Clinician? Toby Capstick Q & A |
| 10:00 – 10:30 | ILD/IPF Session Chair: TBA Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? Mark Jones Q & A |
| 10:30 – 10:45 | Coffee Break |
| 10:45 – 11:30 | Readers', authors',
and editors' perspectives on observational research Chair: Nicolas Roche & Therese Lapperre How to lie with statistics to a chest physician Joan Β. Soriano An Editor’s perspective on observational research David Price Q & A |
| 11:30 – 12:30 | Early career oral abstract presentations Chair: Marc Miravitlles & Dermot Ryan |
| 12:30 – 13:30 | Lunch Break & Poster viewing |
| 13:30 – 15:00 | COPD Session Chair: Bernardino Alcazar & Frits M.E. Franssen Predicting the risk for first COPD Severe Exacerbation Bernardino Alcazar Triple therapy and very severe COPD: Rational for a REG study Chin Kook Rhee New Drugs in COPD: Will they make a real-life difference? Mario Cazzolla Q & A |
| 15:00 – 15:30 | Coffee Break |
| 15:30 – 16:15 | United Airways Disease Session Chair: Piotr Kuna & Stefania Gallo Rhinitis +/- asthma: different diseases? Ralph Mosges (R)evolution of care in CRSwNP Peter Hellings Q & A |
| 16:15 – 17:00 | AI/Digital in respiratory diseases Session Chair: Prof. Job van Boven & Fulvio Braido Can interactions with AIs provide patient support? Alan Kaplan Can digital adherence support prevent disease progression? Amy Chan Q & A |
| 17:00 – 17:45 | PRO/CON – Vaccines Chair: Alberto Papi Pneumococcal vaccine is the most important respiratory vaccine for our high-risk patients to receive PRO: Filipe Froes RSV is the most important respiratory vaccine for our high-risk patients to receive CON: Antonio Anzueto Vote & Summary Discussion Alan Kaplan |
| Saturday, March 22nd, 2025 |
|
| 09:00 – 10:00 | Expansion of biologic use in asthma: where to? Chair: Nikos Papadopoulos & Jennifer Quint Younger age Adnan Custovic Milder disease Alberto Papi Multimorbidities Désirée Larenas-Linnemann Q&A |
| 10:00 – 10:45 |
Bronchiectasis Session Chair: Antonio Anzueto Current and future perspectives in the treatment of bronchiectasis Eva Van Braeckel Q&A |
| 10:45 – 11:00 | Coffee Break |
| 11:00 – 12:15 | Improving severe asthma care - ISAR’s research and quality improvement highlights ISAR’s impact on practice change TBA ISAR quality improvement goal 2024-2025: Improvement of data quality TBA Impact of biologics on new onset of OCS-related outcomes in severe asthma (SOLAR II), and ISAR’s goal of eliminating long-term OCS use TBA Exploring definitions and predictors of severe asthma remission post-biologic (FULL BEAM II) TBA Latest ISAR research on remission in severe asthma (GLEAM and SPOTLIGHT) TBA |
| 12:15 – 13:30 | Joint REG & EAACI Session - RWE and Guidelines Chair: Walter G. Canonica The need for RWE to be included in guidelines Stefano Del Giacco The GRADE system to integrate RWE Holger Schunemann Real-Life experience of guideline creation TBA Discussion |
| 13:30 | Meeting Close |
Key dates & Deadlines
| Early Registration Deadline: |
December 30th, 2024 |
| Abstract Submission Deadline: |
January 15th, 2025 |
| Notification of Abstracts Acceptance: | January 31st, 2025 |
| REG SUMMIT 2025: | March 20-22, 2025 |
| Security Warning: Please be aware of fraudulent websites or emails being presented as coming from the official conference organiser or official housing office. read more |
